# SunRISe-2 (NCT04658862)

> A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04658862
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Urinary Bladder Neoplasms
- Interventions: Cetrelimab; TAR-200; Cisplatin; Gemcitabine; Conventional radiation therapy; Hypo-fractioned radiation therapy
- Enrollment: 518
- Primary outcome: Time from Randomization to the First Bladder Intact Event-free Survival (BI-EFS) event

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 33
- YouTube: 20
- Podcasts: 20

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=sunrise-2-nct04658862

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04658862", "email": "<work email>"}; the inbox owner confirms by the emailed link.